glaucoma: Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
115 |
4. Check minimum number of eventsNone |
115 |
5. Include endpointsNone |
115 |
6. Filter based on genotype QC (FinnGen only) |
113 |
Control definitions (FinnGen only)
- Control exclude
- H7_GLAUCOMA
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H40
- Name in latin
- Glaucoma ex usu medicamenti
Similar endpoints
↥List of similar endpoints to
Glaucoma secondary to drugs
based on the number of shared cases.
Similar with more cases:
- Glaucoma
- Diseases of the eye and adnexa
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 667 | 340 | 320 |
| Only index persons | 593 | 307 | 286 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 54.35 | 54.38 | 54.37 |
| Only index persons | 52.80 | 52.63 | 52.98 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 113 | 53 | 60 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | 53.86 | 51.20 | 56.22 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 115
- Matched controls
- 1150
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
S01ED51
ATC
timolol, combinations; ophthalmic
218.3
154.5
78
11
H40.6
ICD-10 Finland
Glaucoma secondary to drugs
+∞
135.9
102
*
114
Kela drug reimbursment
Glaucoma
325.2
79.9
73
6
H20.0
ICD-10 Finland
Acute and subacute iridocyclitis
31.7
55.7
40
19
H40.0
ICD-10 Finland
Glaucoma suspect
103.9
42.9
45
7
XCW99
NOMESCO Finland
Other investigative procedure of eye
14.9
42.3
47
51
S01ED01
ATC
timolol; ophthalmic
135.2
42.3
43
5
Z96.1
ICD-10 Finland
Presence of intraocular lens
12.1
37.7
50
69
H40.5
ICD-10 Finland
Glaucoma secondary to other eye disorders
+∞
37.6
34
*
S01EE01
ATC
latanoprost; ophthalmic
64.9
37.2
42
10
S01EA05
ATC
brimonidine; ophthalmic
460.3
34.9
33
*
H20.1
ICD-10 Finland
Chronic iridocyclitis
383.2
30.3
29
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
9.1
28.1
45
76
S01EC01
ATC
acetazolamide; systemic
69.8
27.9
31
6
S01EE05
ATC
tafluprost; ophthalmic
+∞
27.2
25
*
S01EC04
ATC
brinzolamide; ophthalmic
174.4
26.9
27
*
A07EC01
ATC
sulfasalazine; oral, rectal
10.8
24.8
31
38
H40.13
ICD-10 Finland
Chronic glaucoma with open ventricular angle
284.3
23.5
23
*
L04AX03
ATC
methotrexate; systemic
8.2
23.1
38
65
Z01.0
ICD-10 Finland
Examination of eyes and vision
6.4
20.8
49
120
XCK00
NOMESCO Finland
Perimetry
22.7
19.5
28
16
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
7.1
17.8
32
59
S01BA01
ATC
dexamethasone; ophthalmic
18.2
17.4
27
19
S01BA04
ATC
prednisolone; ophthalmic
42.3
17.4
21
6
S01EX03, ,
ATC
+∞
17.1
16
*
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
5.3
17.0
76
310
S01BA07
ATC
fluorometholone; ophthalmic
47.8
17.0
20
5
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
5.1
16.9
59
198
CJB10
NOMESCO Finland
Laser discission of secondary cataract
7.9
16.1
25
39
H26.3
ICD-10 Finland
Drug-induced cataract
184.0
15.9
16
*
L04AX01
ATC
azathioprine; systemic
22.3
15.4
22
12
3653A
ICD-9 Finland
Glaucoma, Corticosteroid-induced glaucoma
+∞
14.9
14
*
XCK10
NOMESCO Finland
Photography of fundus of eye
6.5
14.2
27
52
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic
4.4
14.1
62
241
S01EE03
ATC
bimatoprost; ophthalmic
+∞
13.8
13
*
CS1H4
NOMESCO Finland
Retinal nerve fibre layer imaging
+∞
13.8
13
*
S01EC03
ATC
dorzolamide; ophthalmic
+∞
13.8
13
*
S01CA02
ATC
prednisolone and antiinfectives; ophthalmic
157.9
13.8
14
*
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
26.3
13.4
18
8
CKD05
NOMESCO Finland
Puncture of vitreous body with injection of medication
14.8
12.7
21
17
H40.4
ICD-10 Finland
Glaucoma secondary to eye inflammation
+∞
12.7
12
*
S01EC54
ATC
brinzolamide, combinations; ophthalmic
145.2
12.7
13
*
H26.4
ICD-10 Finland
After-cataract
6.4
12.4
23
43
S01EE04
ATC
travoprost; ophthalmic
72.5
11.9
13
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.4
11.4
21
39
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
9.0
10.9
23
31
S01EA03
ATC
apraclonidine; ophthalmic
120.5
10.6
11
*
CHD50
NOMESCO Finland
Shunt operation on anterior chamber
+∞
10.6
10
*
H40.9
ICD-10 Finland
Glaucoma, unspecified
+∞
10.6
10
*
L01BA01
ATC
methotrexate; systemic
13.1
10.5
18
16
H04.10
ICD-10 Finland
Dry eye syndrome
4.7
10.4
28
73
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
9.6
10.4
21
26
H02AB06
ATC
prednisolone; systemic
3.7
10.3
75
388
WX140
NOMESCO Finland
Parabulbar anesthesy
12.3
10.2
18
17
CHD05
NOMESCO Finland
Selective lasertrabeculoplasty
108.6
9.6
10
*
S01ED02
ATC
betaxolol; ophthalmic
+∞
9.5
9
*
S01FA04
ATC
cyclopentolate; ophthalmic
40.1
9.2
11
*
WX100
NOMESCO Finland
Conjunctival surface anesthesia
4.6
9.0
24
62
CS494
NOMESCO Finland
Other visual field testing
54.2
8.8
10
*
H26.2
ICD-10 Finland
Complicated cataract
36.2
8.2
10
*
S01FA02
ATC
scopolamine; ophthalmic
36.2
8.2
10
*
D07XC01
ATC
betamethasone; topical
4.1
7.9
25
73
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.1
7.9
52
244
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
11.2
7.8
14
14
L04AB04
ATC
adalimumab; parenteral
14.7
7.6
12
9
S01EA02
ATC
dipivefrine; ophthalmic
+∞
7.4
7
*
CHD65
NOMESCO Finland
Nonpenetrating glaucoma surgery
+∞
7.4
7
*
M05BA04
ATC
alendronic acid; oral
4.8
7.0
17
40
CS434
NOMESCO Finland
Visual field testing with Humphrey automated perimetry
24.2
6.8
9
*
CKD65
NOMESCO Finland
Pars plana or pars plicata vitrectomy
13.3
6.7
11
9
CS5Z4
NOMESCO Finland
Specialised imaging for glaucoma
19.3
6.4
9
5
L04AA01
ATC
[U] ciclosporin
28.4
6.3
8
*
S01EB01
ATC
pilocarpine; ophthalmic
+∞
6.3
6
*
H22.1*M45
ICD-10 Finland
Iridocyclitis in ankylosing spondylitis
+∞
6.3
6
*
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
9.4
6.2
12
14
H02AB07
ATC
prednisone; oral
3.6
6.2
23
75
S01BC05
ATC
ketorolac; ophthalmic
8.0
6.1
13
18
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
19
50
4.35
6.86
3.3
1.9
40.68
42.49
u/l
0.15
19
42
72
456
2.55
5.50
9.8
6.3
1.21
1.21
mmol/l
0.03
57
387
9
13
7.40
4.25
4.0
2.7
56.22
61.54
%
—
9
13
14
45
3.40
3.79
2.0
1.2
831.54
652.31
u/ml
0.09
14
40
47
284
2.11
3.58
5.4
3.7
15.19
10.30
mg/mmol
0.23
34
176
36
206
2.09
3.10
1.8
1.8
405.21
469.11
pmol/l
1.09
29
174
9
22
4.34
2.95
1.0
1.2
—
—
—
0
0
9
22
4.34
2.95
1.4
2.0
—
—
—
0
0
64
476
1.78
2.36
4.6
3.8
0.00
0.01
estimate
0.50
14
97
64
479
1.76
2.28
4.9
3.8
0.00
0.00
estimate
-0.00
12
85
5
9
5.75
2.23
1.6
1.3
—
—
—
0
0
7
20
3.66
2.09
1.1
1.6
—
—
—
0
0
62
475
1.66
1.92
6.0
5.1
0.00
0.00
estimate
-0.00
14
88
29
181
1.81
1.87
1.8
1.6
1151.74
1201.47
nmol/l
0.12
23
133
13
60
2.32
1.86
3.4
4.1
72.31
77.67
ng/l
0.07
13
52
5
12
4.30
1.84
1.4
3.3
12.60
22.62
nmol/l
—
5
12
12
55
2.32
1.74
4.3
3.2
136.08
132.85
g/l
0.16
12
55
10
42
2.51
1.66
7.4
4.6
59.11
52.62
%
—
10
42
6
20
3.11
1.60
1.8
2.8
20.68
16.68
%
—
6
9
7
27
2.69
1.54
1.0
1.2
—
—
—
0
0
38
272
1.59
1.47
3.6
2.9
986.50
971.29
ng/l
0.01
31
224
6
22
2.82
1.45
2.8
2.2
25.23
25.97
mmol/l
—
6
22
7
29
2.50
1.41
1.3
1.2
0.30
0.22
g/l
—
7
29
83
716
1.57
1.34
4.6
4.0
15.07
14.81
pmol/l
0.42
76
645
8
35
2.38
1.30
4.9
2.9
—
—
—
0
0
98
887
1.71
1.22
5.7
4.6
2.08
1.90
mu/l
0.76
88
806
7
31
2.34
1.12
1.3
1.2
1.44
1.15
g/l
—
7
31
48
381
1.45
1.10
4.6
3.9
—
—
—
0
0
25
175
1.55
1.04
1.8
3.1
2.42
2.45
mmol/l
0.51
20
150
5
22
2.33
1.04
1.4
1.5
—
—
—
0
0
5
22
2.33
1.04
3.8
1.3
—
—
—
0
0
53
435
1.41
0.99
5.6
4.2
35.26
35.69
g/l
0.18
48
413
18
118
1.62
0.98
11.3
7.2
—
—
—
0
0
36
276
1.44
0.98
5.6
2.9
0.09
0.36
e6/l
2.09
31
198
17
110
1.64
0.97
11.4
6.6
103.82
104.30
mmol/l
0.15
17
110
62
525
1.39
0.96
5.9
6.9
14.12
10.58
umol/l
0.39
57
503
18
119
1.61
0.95
1.3
1.4
—
—
—
0
0
16
103
1.64
0.93
8.9
5.2
1.05
1.04
mmol/l
0.06
16
98
6
28
2.20
0.93
3.0
2.5
—
—
—
0
0
15
95
1.67
0.93
3.1
3.4
—
—
—
0
0
8
45
1.83
0.86
1.6
1.8
—
—
—
0
0
8
47
1.75
0.82
3.8
2.6
1.34
1.16
%
—
8
47
34
266
1.39
0.82
5.4
4.0
0.00
0.00
estimate
-0.00
11
84
103
970
1.59
0.75
23.2
13.9
19.01
22.79
mg/l
0.64
88
755
5
25
2.04
0.73
2.0
1.3
—
—
—
0
0
10
61
1.70
0.71
3.3
2.9
4.73
4.55
pmol/l
—
10
51
5
27
1.89
0.69
1.8
2.0
—
—
—
0
0
5
27
1.89
0.69
3.4
1.9
185.00
173.81
%
—
5
27
11
70
1.63
0.68
2.2
1.4
—
—
—
0
0
41
341
1.31
0.66
2.4
1.9
95.66
91.45
pmol/l
0.27
27
176
97
909
1.43
0.65
17.0
13.0
81.52
81.93
ml/min/173m2
0.06
88
737
5
29
1.76
0.64
2.4
1.4
—
—
—
0
0
5
30
1.70
0.62
1.4
1.2
—
—
—
0
0
42
354
1.29
0.61
6.3
3.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.5
—
557.74
—
0
21
8
54
1.52
0.58
3.6
1.3
—
—
—
0
0
23
179
1.36
0.57
1.3
1.3
34.65
40.87
iu/ml
—
8
60
26
207
1.33
0.56
1.6
1.5
22.31
20.64
nmol/l
0.22
21
174
26
207
1.33
0.56
1.8
1.8
1.05
1.53
mg/l
0.36
18
174
22
171
1.35
0.55
1.3
1.2
7.97
13.58
u/ml
—
7
68
39
330
1.28
0.54
2.1
2.4
55.28
57.10
u/l
0.19
32
304
64
582
1.22
0.46
3.4
3.1
—
—
—
0
0
49
434
1.22
0.45
13.5
13.2
1.41
1.25
inr
0.38
12
133
5
31
1.64
0.43
5.8
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.6
—
—
—
0
0
40
448
0.84
0.36
3.1
2.6
—
—
—
0
0
42
377
1.18
0.32
4.8
3.8
28.34
38.95
ng/l
0.39
37
253
106
1078
0.79
0.26
36.3
20.1
4.53
4.53
e12/l
0.01
106
1058
106
1078
0.79
0.26
36.6
20.2
136.49
136.85
g/l
0.09
106
1066
106
1077
0.80
0.26
36.4
20.2
250.59
249.36
e9/l
0.07
106
1058
12
96
1.28
0.25
2.3
1.9
—
—
—
0
0
70
662
1.15
0.25
3.8
3.1
66.59
50.84
u/l
0.59
63
625
26
294
0.85
0.25
3.2
4.6
21.10
21.05
%
0.01
12
150
17
143
1.22
0.25
2.5
1.9
—
—
—
0
0
19
220
0.84
0.24
3.7
2.4
—
—
—
0
0
5
38
1.33
0.23
1.0
5.3
15.40
75.96
u/ml
—
5
38
5
38
1.33
0.23
1.8
2.1
—
—
—
0
0
5
41
1.23
0.22
1.8
2.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.8
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
27
243
1.15
0.19
2.2
1.7
1.62
1.34
mmol/l
0.81
22
202
39
362
1.12
0.18
4.5
5.1
1.30
2.88
ug/l
1.12
34
324
27
247
1.12
0.15
1.4
1.3
0.78
2.03
u/ml
—
6
63
88
863
1.08
0.09
26.3
16.1
14.22
14.82
%
0.67
88
858
9
84
1.08
0.07
2.0
2.4
9.43
5.90
ug/l
—
9
75
9
85
1.06
0.07
2.4
1.8
—
—
—
0
0
90
914
0.93
0.07
4.8
4.0
1.31
1.30
mmol/l
0.03
80
842
96
947
1.08
0.07
5.3
4.5
4.58
4.65
mmol/l
0.31
89
881
18
192
0.93
0.06
2.1
1.4
—
—
—
0
0
98
969
1.08
0.05
5.9
5.0
2.61
2.76
mmol/l
0.93
91
900
11
102
1.09
0.03
13.1
7.2
5.26
5.12
kpa
0.17
11
97
10
107
0.93
0.02
2.3
1.8
—
—
—
0
0
12
114
1.06
0.01
7.1
4.3
26.86
32.18
%
—
7
73
10
103
0.97
0.00
2.3
1.8
—
—
—
0
0
94
943
0.98
0.00
5.5
4.4
1.50
1.45
mmol/l
0.43
86
875
92
921
0.99
0.00
5.1
4.6
6.00
5.94
mmol/l
0.16
84
848
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
0.31
—
0
5
0
5
0.00
0.00
0.0
4.4
—
—
—
0
0
0
5
0.00
0.00
0.0
4.4
—
—
—
0
0
0
5
0.00
0.00
0.0
11.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
5
59
0.84
-0.00
1.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
7.63
—
0
7
5
56
0.89
-0.00
7.0
5.5
24.06
24.84
mmol/l
—
5
56
9
93
0.97
-0.00
2.9
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_GLAUCSECDRUG and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_GLAUCSECDRUG | 1.913 [1.39, 2.64] | < 0.001 |
| Birth year | 0.994 [0.98, 1.0] | 0.14 |
During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 267 females with H7_GLAUCSECDRUG died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_GLAUCSECDRUG | 1.552 [1.14, 2.11] | 0.005 |
| Birth year | 0.988 [0.98, 1.0] | 0.018 |
During the follow-up period (1.1.1998 — 31.12.2019), 59 out of 245 males with H7_GLAUCSECDRUG died.
Mortality risk
Mortality risk for people of age
years, who have H7_GLAUCSECDRUG.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.161% | 0.328% |
| 5 | 1.124% | 1.904% |
| 10 | 2.803% | 4.702% |
| 15 | 5.382% | 8.75% |
| 20 | 9.14% | 14.514% |
Relationships between endpoints
↥Index endpoint: H7_GLAUCSECDRUG – Glaucoma secondary to drugs
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data